• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Drug Compounding: Background, Issues & FDA Oversight

Drug Compounding: Background, Issues & FDA Oversight

9781631173608
661.44 zł
595.29 zł Save 66.15 zł Tax included
Lowest price within 30 days before promotion: 595.29 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Compounding has been traditionally defined as a process where a pharmacist or a physician combines, mixes, or alters ingredients to create a medication tailored to the needs of an individual patient. Traditionally compounded drugs (CDs) are made in response to an individual prescription from a licensed health provider in the context of a pharmacists and health care professionals relationship with a specific patient. This book provides background information on CDs and non-traditional compounding pharmacies relevant to policy discussions. This book will also examine the FDAs regulation of drug compounding and will discuss relevant legal authorities. Specifically, the status of FDAs authority to oversee drug compounding, and the gaps, if any, between state and federal authority will be discussed, as well as how FDA has used its data and authority to oversee drug compounding, and the actions taken or planned by states or national pharmacy organisations to improve oversight of drug compounding.
Product Details
74521
9781631173608
9781631173608

Data sheet

Publication date
2014
Issue number
1
Cover
hard cover
Pages count
123
Dimensions (mm)
155.00 x 230.00
Weight (g)
382
  • Preface; Compounded Drugs; Federal Authority to Regulate the Compounding of Human Drugs; Drug Compounding:: Clear Authority & More Reliable Data Needed to Strengthen FDA Oversight; Statement of Janet Woodcock, Director, Center for Drug Evaluation & Research, Food & Drug Administration. Hearing on Examining Drug Compounding; Testimony of Scott Gottlieb, Resident Fellow, The American Enterprise Institute. Hearing on Examining Drug Compounding; Testimony of Joe Harminson, Owner of DFW Prescriptions, on behalf of the National Community Pharmacists Association. Hearing on Examining Drug Compounding; Index.
Comments (0)